Zobrazeno 1 - 7
of 7
pro vyhledávání: '"Veronique de Jager"'
Autor:
Irina Kontsevaya, Jan Heyckendorf, Frauke Koops, Doris Hillemann, Torsten Goldmann, Caryn M. Upton, Veronique De Jager, Andreas Diacon, Christoph Lange
Publikováno v:
Microbiology Spectrum, Vol 11, Iss 6 (2023)
ABSTRACT We assessed the performance of a novel real-time PCR-based transrenal DNA (trDNA) assay for the specific detection of Mycobacterium tuberculosis as a candidate marker of the early anti-tuberculosis therapy response. The study was performed o
Externí odkaz:
https://doaj.org/article/adb1a09c98f64eab8c5246dae185bfa0
Autor:
Ahmed A. Abulfathi, Veronique de Jager, Elana van Brakel, Helmuth Reuter, Nikhil Gupte, Naadira Vanker, Grace L. Barnes, Eric Nuermberger, Susan E. Dorman, Andreas H. Diacon, Kelly E. Dooley, Elin M. Svensson
Publikováno v:
Frontiers in Pharmacology, Vol 12 (2021)
Background: Meropenem is being investigated for repurposing as an anti-tuberculosis drug. This study aimed to develop a meropenem population pharmacokinetics model in patients with pulmonary tuberculosis and identify covariates explaining inter-indiv
Externí odkaz:
https://doaj.org/article/cadb0a5433cf4817a6465fe5572efa83
Autor:
Andreas Diacon, ProfPhD, Sachiko Miyahara, PhD, Rodney Dawson, PhD, Xin Sun, PhD, Evelyn Hogg, Kathleen Donahue, MA, Michael Urbanowski, PhD, Veronique De Jager, MD, Courtney V Fletcher, ProfPharmD, Richard Hafner, MD, Susan Swindells, ProfMBBS, William Bishai, ProfMD
Publikováno v:
The Lancet Microbe, Vol 1, Iss 2, Pp e84-e92 (2020)
Summary: Background: Clinical studies suggest that isoniazid contributes rapid bacterial killing during the initial 2 days of tuberculosis treatment, but that the activity of isoniazid declines substantially after day 3 of treatment. In this 14-day,
Externí odkaz:
https://doaj.org/article/18657402e09d414b9438792656058339
Autor:
Veronique De Jager, Nikhil Gupte, Silvia Nunes, Grace L. Barnes, Rob Christiaan van Wijk, Joni Mostert, Susan E. Dorman, Ahmed A. Abulfathi, Caryn M. Upton, Alan Faraj, Eric L. Nuermberger, Gyanu Lamichhane, Elin M. Svensson, Ulrika S. H. Simonsson, Andreas H. Diacon, Kelly E. Dooley
Publikováno v:
American Journal of Respiratory and Critical Care Medicine, 205, 1228-1235
American Journal of Respiratory and Critical Care Medicine, 205, 10, pp. 1228-1235
Am J Respir Crit Care Med
American Journal of Respiratory and Critical Care Medicine, 205, 10, pp. 1228-1235
Am J Respir Crit Care Med
RATIONALE: Carbapenems are recommended for treatment of drug-resistant tuberculosis. Optimal dosing remains uncertain. OBJECTIVES: To evaluate the 14-day bactericidal activity of meropenem, at different doses, with or without rifampin. METHODS: Indiv
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::533bcc4e3a8f6b5b5a417c2f96b7a097
https://doi.org/10.1164/rccm.202108-1976OC
https://doi.org/10.1164/rccm.202108-1976OC
Autor:
Yuanxi Zou, Veronique de Jager, Anneke C. Hesseling, Andreas H. Diacon, Lubbe Wiesner, Joni Mostert, Elin M. Svensson, Anthony Garcia‐Prats
Publikováno v:
British Journal of Clinical Pharmacology.
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::23900eb0f67ca9fc5570439e62a94b13
https://doi.org/10.1111/bcp.15672
https://doi.org/10.1111/bcp.15672
Autor:
Lindsey H M, Te Brake, Veronique, de Jager, Kim, Narunsky, Naadira, Vanker, Elin M, Svensson, Patrick P J, Phillips, Stephen H, Gillespie, Norbert, Heinrich, Michael, Hoelscher, Rodney, Dawson, Andreas H, Diacon, Rob E, Aarnoutse, Martin J, Boeree
Publikováno v:
The European Respiratory Journal
article-version (VoR) Version of Record
article-version (VoR) Version of Record
Background Accumulating data indicate that higher rifampicin doses are more effective and shorten tuberculosis (TB) treatment duration. This study evaluated the safety, tolerability, pharmacokinetics, and 7- and 14-day early bactericidal activity (EB
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid________::7276b3da71f0988c1fbdda91c60bc528
https://pubmed.ncbi.nlm.nih.gov/33542056
https://pubmed.ncbi.nlm.nih.gov/33542056
Autor:
Lindsey te Brake, Veronique de Jager, Kim Narunsky, Naadira Vanker, Elin M. Svensson, Patrick P.J Phillips, Stephen H Gillespie, Norbert Heinrich, Michael Hoelscher, Rodney Dawson, Andreas H. Diacon, Rob E. Aarnoutse, Martin J. Boeree, PanACEA Consortium Group
Publikováno v:
SSRN Electronic Journal.
Background: Accumulating data indicate that higher rifampicin doses may be more effective and shorten tuberculosis treatment duration. This study evaluated the safety, tolerability, pharmacokinetics, and 14-day early bactericidal activity (EBA) of in
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::00d6061a2c84049912e24ee1c533234b
https://doi.org/10.2139/ssrn.3550042
https://doi.org/10.2139/ssrn.3550042